Where does MDMA-assisted therapy go from here?
Psychedelic treatments face a challenge from the FDA
![woman with mouth open and a pill on her tongue](https://cdn.mos.cms.futurecdn.net/YAfp4WgwAsuvCEXK92UbQo-415-80.jpg)
The U.S. Food and Drug Administration has delivered a "critical blow" against efforts to bring psychedelics into the mainstream, said Vox. The agency rejected an application from drugmaker Lykos Therapeutics to use the drug MDMA as a treatment — combined with talk therapy — for post-traumatic stress. The rejection "does not fully quash" the psychedelic movement, but "it will delay it."
The dismissal came after studies used to support the MDMA effort "missed serious side effects," The Wall Street Journal said, and had problems with bias. The biggest problem? Some subjects told researchers "their thoughts of suicide worsened" amidst the testing, raising concerns the Journal said were not fully captured in the trial reports. "The data is reliable," said Lykos chief executive Amy Emerson.
Veterans groups have pushed for approval of psychedelics to treat trauma issues, and their cause has bipartisan support in Congress. For now, at least, that is not enough. "It's clear that the path to creating access to safe, psychedelic-assisted therapy is not going to run through Washington, D.C.," Healing Action Fund's Taylor West said to The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What did the commentators say?
The FDA's decision "will likely only delay psychedelic medicine's official debut" as an approved treatment, Jonathan Lambert said in The Atlantic. But it could prompt a change in one of the most "poorly understood and hotly contested" issues in psychedelic therapy: the therapy itself. Advocates believe combining the drugs with talk therapy can "catalyze changes" neither accomplishes on its own. Sussing out the effects of therapy is difficult, though — and the FDA does not regulate therapy — which is why drug companies may be tempted simply to focus on the benefit of drugs alone. That could turn psychedelics "into just more pills to pop."
"Psychedelic drug development is a fraught process by nature," Arizona State University's Benjamin Y. Fong said in an interview with The Conversation. The drugs do put users in a "severely altered state" that can render them vulnerable, after all. Given that, some observers believe it will be "nearly impossible to avoid accusations of impropriety" as researchers make their way forward. They will venture ahead, but the latest setback shows how psychedelics face "unique obstacles on the way to FDA approval."
What next?
"It's not yet clear" how the FDA decision will affect future applications for psychedelic treatments, said Nature. Some advocates worry that future applicants will drop the therapy components of their proposed treatments in order to get government approval. That would be "contrary to the ethos of many who have been pressing for approval and acceptance of these substances," said Harvard bioethics expert Glenn Cohen.
"Is the medical system ready for any psychedelic?" asked Time. Any drug that does get approval will have to overcome an "overstretched therapeutic workforce, insurance headaches, concerns about safety and illicit use and logistical issues" to be fully implemented in a care setting. Getting MDMA in front of the FDA took "decades of advocacy." The final push will remain strenuous. Psychedelics are "novel treatments," said Dr. Jonathan Alpert, chair of the American Psychiatric Association's Council on Research, "and they inevitably raise novel questions."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Joel Mathis is a writer with 30 years of newspaper and online journalism experience. His work also regularly appears in National Geographic and The Kansas City Star. His awards include best online commentary at the Online News Association and (twice) at the City and Regional Magazine Association.
-
7 recipes for every kind of fall cooking occasion
The Week Recommends Marinated feta; go-to chocolate cake; a fresh way with Brussels: Autumn is not going to know what hit it
By Scott Hocker, The Week US Published
-
Why is a government shutdown possible before the election?
Today's Big Question A fight over immigration, spending and the future of House Speaker Mike Johnson
By Joel Mathis, The Week US Published
-
DOJ charges 2 in white nationalist 'Terrorgram' plot
Feds say Dallas Humber and Matthew Allison were plotting assassinations through a terrorist network on Telegram
By Peter Weber, The Week US Published
-
Psychedelic drugs and treating mental illness
The Explainer Scientists claim hallucinogenics could help treat depression and anxiety, but not everyone is convinced
By Elizabeth Carr-Ellis, The Week UK Published
-
Mold, bugs at listeria-linked Boar's Head meat plant
Speed Read Food safety inspectors reported many violations at a Virginia plant that has been linked to a nationwide deli meat recall
By Peter Weber, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
The battle for abortion buffer zones
The Explainer A 2023 law banning protests around clinics remains unenforced amid dispute over 'silent prayer'
By Harriet Marsden, The Week UK Published
-
WHO declares mpox a global health emergency
Speed Read An outbreak of the viral disease formerly known as monkeypox continues to spread in Africa
By Rafi Schwartz, The Week US Published
-
Why gonorrhoea is becoming 'untreatable'
In the Spotlight Infections hit record high as experts warn about rise in antibiotic-resistant cases
By Elizabeth Carr-Ellis, The Week UK Published
-
Can dementia be defeated?
Today's Big Question A new report identifies 14 risk factors
By Joel Mathis, The Week US Published
-
Deadly 'brain-eating' amoebas could be spreading thanks to climate change
Under the Radar Naegleria fowleri causes rare and lethal infection, but recent uptick in cases suggests it is thriving in warming waters
By Harriet Marsden, The Week UK Last updated